Literature DB >> 4000412

Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous anti-opioid substrates?

J S Han, X Z Ding, S G Fan.   

Abstract

Cholecystokinin octapeptide (CCK-8), given intracerebroventricularly (icv) or intrathecally (ith) at the dose range of 0.25-4.0 ng, dose-dependently antagonised the effect of morphine analgesia and electroacupuncture analgesia (EAA) in the rat. That CCK-8 antiserum was capable of reversing the tolerance to EAA and changing the non-responders of EAA into responders suggest CCK-8 to be the endogenous anti-opioid substrate and that blocking the effect of CCK-8 may prove to be a powerful way of augmenting the effect of morphine analgesia and EA analgesia.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4000412     DOI： 10.1016/0143-4179(85)90038-1

Source DB:  PubMed          Journal:  Neuropeptides        ISSN： 0143-4179            Impact factor:   3.286


  11 in total

1.  A tribute to Professor Ji-Sheng Han.

Authors:  Albert Cheung Hoi Yu
Journal:  Neurochem Res       Date:  2008-04-12       Impact factor: 3.996

2.  Effect of devazepide reversed antagonism of CCK-8 against morphine on electrical and mechanical activities of rat duodenum in vitro.

Authors:  Man-Ying Xu; Hui-Ming Lu; Shu-Zhen Wang; Wen-Yan Shi; Xin-Chun Wang; Dong-Xiao Yang; Chun-Xiao Yang; Li-Zhuang Yang
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

3.  PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.

Authors:  Z Wiesenfeld-Hallin; X J Xu; J Hughes; D C Horwell; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.

Authors:  X J Xu; Z Wiesenfeld-Hallin; J Hughes; D C Horwell; T Hökfelt
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

Review 5.  What intrinsic factors influence responsiveness to acupuncture in pain?: a review of pre-clinical studies that used responder analysis.

Authors:  Yu-Kang Kim; Ji-Yeun Park; Seung-Nam Kim; Mijung Yeom; Seungmin Lee; Ju-Young Oh; Hyangsook Lee; Younbyoung Chae; Dae-Hyun Hahm; Hi-Joon Park
Journal:  BMC Complement Altern Med       Date:  2017-05-25       Impact factor: 3.659

6.  Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide.

Authors:  Yin Yang; Qian Li; Qi-Hua He; Ji-Sheng Han; Li Su; You Wan
Journal:  Exp Mol Med       Date:  2018-05-21       Impact factor: 8.718

7.  Patch clamp: a powerful technique for studying the mechanism of acupuncture.

Authors:  D Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-22       Impact factor: 2.629

8.  Over-expression of CCK1 Receptor Reverse Morphine Dependence.

Authors:  Lijing Hao; Di Wen; Hongyan Gou; Feng Yu; Bin Cong; Chunling Ma
Journal:  Int J Pept Res Ther       Date:  2018-04-02       Impact factor: 1.931

Review 9.  The Involvement of Descending Pain Inhibitory System in Electroacupuncture-Induced Analgesia.

Authors:  Qiuyi Lv; Fengzhi Wu; Xiulun Gan; Xueqin Yang; Ling Zhou; Jie Chen; Yinjia He; Rong Zhang; Bixiu Zhu; Lanying Liu
Journal:  Front Integr Neurosci       Date:  2019-08-21

Review 10.  Non-Opioid Peptides Targeting Opioid Effects.

Authors:  Katarzyna Kaczyńska; Piotr Wojciechowski
Journal:  Int J Mol Sci       Date:  2021-12-19       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.